6533b860fe1ef96bd12c3c43
RESEARCH PRODUCT
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
Angelo Maria PattiRosaria Vincenza GiglioNikolaos PapanasDragos SerbanAnca Pantea StoianKalliopi PafiliKhalid Al RasadiKanya RajagopalanAli A. RizviMarcello CiaccioRizzo Manfredisubject
cardiovascular riskMedicine (General)Cardiovascular risk Free fatty acidsGLP-1 Incretins Metabolism Type 2 diabetes Fatty Acids Nonesterified Humans Diabetes Mellitus Type 2 Insulin Resistanceendocrine system diseasesfree fatty acidsType 2 diabetesReviewGeneral MedicineFatty Acids NonesterifiedR5-920Diabetes Mellitus Type 2HumansInsulin ResistanceGLP-1metabolismincretinsdescription
The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and cardiovascular outcomes. Dietary Free Fatty Acids (FFA) regulate metabolic and anti-inflammatory processes through their action on incretins. Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for T2DM. To comprehensively review the available evidence for the potential role of FFA receptor agonists in the treatment of T2DM, we performed an electronic database search assessing the association between FFAs, T2DM, inflammation, and incretins. Evidence indicates that FFA1-4 agonism increases insulin sensitivity, induces body mass loss, reduces inflammation, and has beneficial metabolic effects. There is a strong inter-relationship between FFAs and incretins. FFA receptor agonism represents a potential target for the treatment of T2DM and may provide an avenue for the management of cardiometabolic risk in susceptible individuals. Further research promises to shed more light on this emerging topic.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 | Medicina |